Patented biomarker for cardiac injury. 

Direct Comparison of cMyC With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction

Study

1st Multicentric study (9 centres) to assess the diagnostic and prognostic value of cMyC in patients presenting with possible AMI 1954 patients presenting at emergency with symptoms of AMI. Onset of chest pain <12 hours.  cMyC, hs-Tn and standard Tn concentrations measured at presentation.  Final diagnosis of AMI independently adjudicated.

Prognosis endpoint : long-term mortality.
cMyC 0/1h algorithm for triaging chest pain patients suspected of AMI (Acute Myocardial Infarction)
cMyC 0/1h algorithm for triaging chest pain patients suspected of AMI (Acute Myocardial Infarction)

Conclusion

  • cMyC, hs-TnT and hs-TnI  exhibit similar diagnostic accuracy in the entire cohort.
  • cMyC > hs-TnT and hs-TnI in terms of diagnostic accuracy for patients with chest pain <3 hours (early presenters ).
  • Design of a rule-in/rule-out pathway using cMyC to compare discriminative power in a clinical setting.
  • cMyC has correctly triaged more patients than hs-TnT or hs-TnI.
  • The combination of cMyC with hs-cTnT or standard-sensitivity cTnI (but not hs-cTnI) led to an increase in of discriminative power.

Additional documents

Data Supplement Publication: Circulation (2017-09-26)

Correction Statement Publication: Circulation (2017-12-19)

Using cMyC to triage on first blood draw results in fewer patients in grey zone compared with hs-cTnT and hs-cTnI.